Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

Cancer Res (2025) 85 (8_Supplement_1): 4294.

Discover comprehensive insights into approved therapeutics and research developments targeting Prostate-Specific Membrane Antigen (PSMA). This product provides detailed competitor analysis, R&D stages ...

A newly developed radiolabeled antibody that targets the cancer antigen IL13Rα2 has been found to be highly specific, binding ...

There have never been LUAD-specific molecules and cancer antigens. On the other hand, we have reported that XAGE1 cancer-testis antigen expression is comparatively specific in LUAD and XAGE1 elicits ...

The dual-targeting approach helps to prevent relapses by addressing the variability among cancer cells in antigen expression. Natural killer (NK) cell function is suppressed by transforming growth ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

RNA-based technologies are a powerful molecular biology toolbox, empowering scientists to decipher the complexities of living ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...